[ad_1]
Hollister, California, June 24, 2021 (Global News Agency)-Alpha Teknova, Inc. (“Teknova”) (NASDAQ:TKNO), a leading supplier of key reagents for the development and production of biopharmaceutical products, including drug therapies, novel vaccines and molecular diagnostics, today announced that its expanded initial public offering of 6,000,000 shares of common stock is priced at $16.00 per share to the public. In addition, Teknova has granted the underwriters a 30-day option to purchase up to 900,000 common shares at the public offering price (minus underwriting discounts and commissions). Teknova will provide and sell all common shares.
Teknova’s common stock is expected to begin trading on the Nasdaq Global Market on Friday, June 25, 2021, under the symbol “TKNO”. Before deducting underwriting discounts and commissions and Teknova’s issuance fees payable, the total proceeds of the issuance are estimated to be approximately US$96 million, excluding the exercise of any option of the underwriters to purchase additional shares. The issuance is expected to be completed on or around June 29, 2021, subject to customary closing conditions.
Cowen and William Blair will serve as joint bookrunners for this issue. BTIG and Stephens Inc. served as joint managers. Paul Hastings LLP provided legal counsel to Teknova, and DLA Piper LLP (USA) provided legal counsel to the underwriters. Perella Weinberg Partners acted as Teknova’s capital market advisor.
A kind of…
The full story on Benzinga.com
[ad_2]
Source link
